首页> 外文期刊>World Journal of Gastroenterology >Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer
【24h】

Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer

机译:DNA错配修复不足与泰国散发性结直肠癌患者预后良好相关

获取原文
           

摘要

AIM: To determine the prognostic significance of deficient mismatch repair (dMMR) and BRAF V600E in Thai sporadic colorectal cancer (CRC) patients. METHODS: We studied a total of 211 out of 405 specimens obtained from newly diagnosed CRC patients between October 1, 2006 and December 31, 2007 at Siriraj Hospital, Mahidol University. Formalin-fixed paraffin-embedded blocks of CRC tissue samples were analyzed for dMMR by detection of MMR protein expression loss by immunohistochemistry or microsatellite instability using polymerase chain reaction (PCR)-DHPLC. BRAF V600E mutational analysis was performed in DNA extracted from the same archival tissues by two-round allele-specific PCR and analyzed by high sensitivity DHPLC. Associations between patient characteristics, MMR and BRAF status with disease-free survival (DFS) and overall survival (OS) were determined by Kaplan-Meier survival plots and log-rank test together with Cox’s proportional hazard regression. RESULTS: dMMR and BRAF V600E mutations were identified in 31 of 208 (14.9%) and 23 of 211 (10.9%) tumors, respectively. dMMR was more commonly found in patients with primary colon tumors rather than rectal cancer (20.4% vs 7.6%, P =0.01), but there was no difference in MMR status between the right-sided and left-sided colon tumors (20.8% vs 34.6%, P = 0.24). dMMR was associated with early-stage rather than metastatic disease (17.3% vs 0%, P = 0.015). No clinicopathological features such primary site or tumor differentiation were associated with the BRAF mutation. Six of 31 (19.3%) samples with dMMR carried the BRAF mutation, while 17 of 177 (9.6%) with proficient MMR (pMMR) harbored the mutation (P = 0.11). Notably, patients with dMMR tumors had significantly superior DFS (HR = 0.30, 95%CI: 0.15-0.77; P = 0.01) and OS (HR = 0.29, 95%CI: 0.10-0.84; P = 0.02) compared with patients with pMMR tumors. By contrast, the BRAF V600E mutation had no prognostic impact on DFS and OS. CONCLUSION: The prevalence of dMMR and BRAF V600E in Thai sporadic CRC patients was 15% and 11%, respectively. The dMMR phenotype was associated with a favorable outcome.
机译:目的:确定缺陷错配修复(dMMR)和BRAF V600E在泰国散发性结直肠癌(CRC)患者中的预后意义。方法:我们在2006年10月1日至2007年12月31日期间在Mahidol大学Siriraj医院从新诊断的CRC患者获得的405个样本中总共研究了211个样本。使用聚合酶链反应(PCR)-DHPLC通过免疫组化或微卫星不稳定性检测MMR蛋白表达损失来分析CRC组织样品中福尔马林固定石蜡包埋的块的dMMR。通过两轮等位基因特异性PCR对从相同档案组织中提取的DNA进行BRAF V600E突变分析,并通过高灵敏度DHPLC进行分析。患者特征,MMR和BRAF状态与无病生存期(DFS)和总体生存期(OS)之间的关联是通过Kaplan-Meier生存图,对数秩检验以及Cox比例风险回归确定的。结果:dMMR和BRAF V600E突变分别在208个肿瘤中的31个(14.9%)和211个肿瘤中的23个(10.9%)中被鉴定出。 dMMR在原发性结肠肿瘤而不是直肠癌患者中更常见(20.4%对7.6%,P = 0.01),但右侧和左侧结肠肿瘤之间的MMR状态无差异(20.8%对34.6%,P = 0.24)。 dMMR与早期而非转移性疾病相关(17.3%vs 0%,P = 0.015)。没有BRAF突变与临床病理特征如原发部位或肿瘤分化有关。 dMMR的31个样本中有6个(19.3%)携带了BRAF突变,而MMR(pMMR)熟练的177个样本中有17个(9.6%)携带了BRAF突变(P = 0.11)。值得注意的是,dMMR肿瘤患者的DFS(HR = 0.30,95%CI:0.15-0.77; P = 0.01)和OS(HR = 0.29,95%CI:0.10-0.84; P = 0.02)显着优于DFS患者pMMR肿瘤。相比之下,BRAF V600E突变对DFS和OS没有预后影响。结论:泰国散发性CRC患者中dMMR和BRAF V600E的患病率分别为15%和11%。 dMMR表型与良好的预后相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号